FDA Warns Consumers of Hidden Sildenafil and Tadalafil in Over-the-Counter Male Sexual Enhancement Products

FDA Warns Consumers of Hidden Sildenafil and Tadalafil in Over-the-Counter Male Sexual Enhancement Products

The U.S. Food and Drug Administration has issued safety alerts identifying multiple over-the-counter male sexual enhancement products that contain undeclared sildenafil, tadalafil, or related analogs. Laboratory analysis confirmed the presence of these prescription phosphodiesterase type 5 (PDE5) inhibitors, which are not listed on product labels. The agency determined that such products are adulterated under the Federal Food, Drug, and Cosmetic Act because PDE5 inhibitors are approved only as prescription drugs [1][2].

The findings coincide with CDC reports documenting adverse events linked to these tainted supplements. Data suggest an association with serious outcomes including hospitalizations [3].

What this means

The presence of hidden PDE5 inhibitors links these products to potential sudden drops in blood pressure, an effect associated with increased risk when combined with nitrates. The adulterated status reflects the regulatory boundary that dietary supplements may not contain prescription drug ingredients. FDA safety alerts and CDC field notes document a pattern of laboratory detections and reported clinical events spanning 2022 through 2024.

FDA Laboratory Findings

The FDA has maintained an updated database through 2024 listing tainted sexual enhancement products in which laboratory testing detected sildenafil, tadalafil, vardenafil, or structural analogs not declared on the label [1]. These detections form the basis for the agency’s ongoing safety alerts.

Documented Clinical Risks

The CDC’s Morbidity and Mortality Weekly Report described adverse events associated with use of tainted male sexual enhancement supplements, including cases that resulted in hospitalization [3]. FDA safety notices state that the undeclared ingredients have been linked to severe hypotension, dizziness, syncope, myocardial infarction, or stroke, particularly in the presence of nitrates [2].

Regulatory Classification and Timeline

In March 2024 the FDA reiterated that products containing hidden PDE5 inhibitors are considered adulterated and illegal for sale as dietary supplements, given that these active ingredients require medical supervision and a prescription [2]. The agency has continued to receive reports of adverse events tied to such products from 2023 to 2024, building on earlier documentation from 2022 [3].

Limitations

The alerts reflect only sampled and tested products; the rapidly evolving marketplace may contain additional untested adulterated items. Data is U.S.-centric and does not quantify total prevalence or capture all international incidents.